Thermo Fisher Scientific Inc., US8835561023

Guggenheim keeps USD 740 target for Thermo Fisher Scientific stock

Published on 10/20/2026 at 11:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Guggenheim keeps a USD 740 target ahead of October 21 results. Thermo Fisher Scientific stock costs EUR 609.10 on October 20, 2026.

Targets and results date

Guggenheim maintained a USD 740.00 target on October 15, 2026.
Second-quarter revenue reached USD 11.99 billion, up 10.00 percent year over year.
Thermo Fisher Scientific stock trades at EUR 609.10 at 11:05 a.m. CEST at Lang & Schwarz on October 20, 2026.
Third-quarter results are scheduled for October 21, 2026, before the US market opens.

Bunte Pop-Art-Illustration eines Wissenschaftlers mit Reagenzglas im Comic-Stil — Pop-Art-Comic feiert Thermo Fisher Sci. US8835561023 mit farbenfrohem Wissenschaftler, Reagenzglas und knalligen Comic-Explosionslinien, Illustration mit AI erstellt.

Thermo Fisher Scientific Inc. (US8835561023) stock was trading at EUR 609.10 at Lang & Schwarz on October 20, 2026, as Guggenheim maintained its USD 740.00 price target ahead of the company’s third-quarter results. According to Investing.com on October 15, 2026, the research firm kept its Buy rating and USD 740.00 target.

Analyst target meets earnings date

The target arrives before Thermo Fisher’s scheduled third-quarter report on October 21, 2026. The company said in an Thermo Fisher Scientific release that results would be published before the US market opens, followed by a conference call at 7:00 a.m. ET.

Expectations are already quantified. El Fondo reported on October 11, 2026, that analysts expected third-quarter adjusted earnings per share of USD 6.47 and revenue of USD 12.06 billion. A separate estimate cited adjusted earnings per share of USD 6.40.

What does the second quarter imply?

The benchmark is the second quarter ended June 28, 2026. Thermo Fisher reported adjusted earnings per share of USD 6.03 and revenue of USD 11.99 billion, compared with consensus of USD 5.72 and USD 11.71 billion, respectively, according to Investing.com. Revenue increased 10.00 percent year over year, while adjusted operating margin rose to 22.80 percent from 21.90 percent.

Three recent company milestones

On September 15, 2026, Thermo Fisher and Mayo Clinic launched Precure, LLC. On September 28, 2026, the company signed a reseller agreement with Evosep for global distribution of the Evosep Eno platform. On October 5, 2026, Thermo Fisher reported that its proteomics platforms helped identify 2,762 genetic-protein links in Singapore’s PRECISE-SG100K study, as reported by El Fondo.

The next dated event is the third-quarter results release on October 21, 2026, before the US market opens. Management’s update on organic growth and margins will determine whether the USD 740.00 target still leaves room above the latest NYSE level of USD 679.38 on October 19, 2026.

Valuation meets the results test

Thermo Fisher Scientific had a market capitalization of USD 251.2 billion and a 52-week range of USD 435.27 to USD 704.00 as of October 19, 2026. The range places the latest NYSE level below the annual high, while the upcoming report offers the next test of the company’s growth and margin profile.

Thermo Fisher Scientific stock was trading at EUR 609.10 at Lang & Schwarz on October 20, 2026 at 11:05 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Thermo Fisher Scientific stock.